Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
Year: 2018
Type: erratum
Abstract: In the original article, we neglected to include the funder **NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation**. The revised “FUNDING” should read:This work is supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex’s Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation and COG SDC grant U10CA180899.This revision in “Funding” is the only revision. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Source: Frontiers in Immunology
Institutions: New York Medical College, Levine Children's Hospital, Boston Children's Hospital, Harvard University, Dana-Farber Cancer Institute, University of Florida, University of California San Diego, Moores Cancer Center, National Institutes of Health, National Cancer Institute, University of Southern California, Children's Hospital of Los Angeles, Texas Tech University Health Sciences Center, United Therapeutics (United States), St. Jude Children's Research Hospital, Seattle Children's Hospital, University of Washington, Children's Hospital of Philadelphia, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Funder: National Cancer Institute
OpenAlex ID: W4239450302